DENVER, COLORADO, July 19 — Today ArcScan, Inc. (ArcScan) announced the appointment of J. Erik Giphart, Ph.D., to succeed Andy Levien as its new CEO. Mr. Giphart is working closely with long-term investor Shanghai Haohai Biological Technology Co. Ltd. (Haohai), developing specific goals to advance ultrasound imaging in Chinese and US markets and to capitalize on the organization’s intellectual property and engineering team.
Prior to becoming the CEO, Mr. Giphart was the Vice President of Engineering at ArcScan for five years with additional responsibilities for operations as well as regulatory and quality assurance. His strategic leadership expertise as a CTO and R&D leader is complemented by more than 20 years of scientific research, medical device design and development, and bringing new technology to market. Mr. Giphart has a master’s degree in electrical engineering from Delft University of Technology, Delft, the Netherlands, and a PhD in biomedical engineering from Boston University.
“As a leading Chinese manufacturer of IOL lenses, we see our continued cooperation with ArcScan as a reflection of our strategy to create differentiated products in the medical industry,” said Olivia Chen, Executive Director of Haohai. “We are enthused about adding ArcScan’s team and its unique, high-quality imaging to our portfolio in China following the recent NMPA approval.”
Using ultrasound, the Insight 100 images the entire anterior segment of the eye including behind the iris, providing insight that is particularly valuable for pIOL sizing, identifying anatomical aberrations, and assessing keratoconus.
“As we develop AI and other technological advances, the potential benefits are exciting, and I am confident this will be an industry-changing instrument.” said Mr. Giphart. “I look forward to spending time listening to our customers and implementing further practical improvements in the Insight 100. In parallel, we aim to continue to improve our customer service and operational efficiency. ArcScan is very grateful for all the shareholder’s continued support and especially that of the Brown family and Haohai.”
About ArcScan Insight® 100
Headquartered in Golden, Colorado, ArcScan, Inc. is a developer of ultrasound imaging technology for use in ophthalmology. Blending AI, ultrasound, and robotics, ArcScan cracked the code for repeatability and consistency in its images. Now poised for further expansion in China, ArcScan is refining its offering with efficacy and efficiency in mind. Its flagship product, the Insight® 100, is a computer-controlled high-frequency ultrasound device designed to equip ophthalmologists with precise, detailed images of the entire anterior segment of the eye including the area behind the iris. The Insight® 100 has been granted FDA marketing clearance, CE approval and NMPA Certification and has been the subject of dozens of studies demonstrating the validity and applicability of its ultrasound imaging. ArcScan has 19 patents surrounding its unique approach to ophthalmic imaging and additional patent applications are in process. For more information about ArcScan, Inc. and the Insight 100, please visit https://www.arcscan.com.
Shanghai Haohai Biological Technology Co., Ltd.
Shanghai Haohai Biological Technology Co., Ltd. is a leading company in the PRC focusing on the research and development and manufacturing and sales of biomedical materials. Haohai strategically targets fast-growing therapeutic areas including ophthalmology, medical aesthetics and wound care, orthopedics and anti-adhesion, and hemostasis. Haohai is a leading Chinese ophthalmology and medical aesthetics company headquartered in Shanghai and is publicly traded on the Hong Kong (6826.HK) and Shanghai (688366.SH) stock exchanges.